Company news

Allogene Therapeutics, Inc. news in 2025

Allogene Therapeutics, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Allogene Therapeutics Reports Favorable Result for Servier in Arbitration with Cellectis

December 15, 2025

Allogene Therapeutics Reports Third Quarter 2025 Financial Results and Business Update

November 6, 2025

Allogene Therapeutics Announces ALPHA3 Trial-in-Progress Poster Presentation at ASH Annual Meeting

November 3, 2025

Allogene Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update

October 30, 2025

Allogene Therapeutics Announces Participation in Upcoming Investor Conference

August 27, 2025

Allogene Therapeutics Reports Second Quarter 2025 Financial Results and Business Update

August 13, 2025

Allogene Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update

August 6, 2025

Allogene Therapeutics Moves Forward with Standard Fludarabine and Cyclophosphamide (FC) Lymphodepletion Regimen in the ALPHA3 Trial for Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation for Large B-Cell Lymphoma

August 1, 2025

Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCO

June 1, 2025

Allogene Therapeutics Announces ASCO 2025 Abstract Publication Featuring Oral Presentation of ALLO-316 in Kidney Cancer and ALPHA3 TIP Poster for Cema-Cel

May 22, 2025

Allogene Therapeutics Reports First Quarter 2025 Financial Results and Business Update

May 13, 2025

Allogene Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update

May 6, 2025

Allogene Therapeutics to Present Updated ALLO-316 Clinical Results in Kidney Cancer in Oral Presentation and ALPHA3 Trial-in-Progress Poster for Cema-Cel at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

April 23, 2025

Allogene Granted Three U.S. FDA Fast Track Designations (FTD) for ALLO-329, a Next-Generation Dual-Targeted CD19/CD70 Allogeneic CAR T, for the Treatment of Lupus, Myositis and Scleroderma

April 7, 2025

Allogene Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update

March 13, 2025

Allogene Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update

March 3, 2025

Allogene Therapeutics Announces Participation in March Investor Conference

February 26, 2025

Allogene Therapeutics Expands Strategic Partnership with Foresight Diagnostics to Advance Joint Development Activities Outside the US Across Europe, UK, Canada, and Australia

February 25, 2025

Allogene Therapeutics Announces Publication of Durable Response Data from Phase 1 ALPHA/ALPHA2 Trials of the Allogeneic CAR T Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma in the Journal of Clinical Oncology

February 12, 2025

Allogene Therapeutics Announces Participation in February Investor Conferences

February 3, 2025

Allogene Therapeutics Announces Benjamin M. Beneski as Senior Vice President and Chief Technical Officer

January 28, 2025

Allogene Therapeutics Secures U.S. FDA IND Clearance for ALLO-329, Advancing its Next-Generation Allogeneic CAR T into Autoimmune Diseases

January 27, 2025

Calls in 2025

Decks in 2025